Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Unicycive Therapeutics submits NDA to FDA for Oxylanthanum Carbonate (OLC) to treat hyperphosphatemia in CKD dialysis patients, aiming for a best-in-class therapy with reduced pill burden.
Highlighted Terms
Related News
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Unicycive Therapeutics submits NDA to FDA for Oxylanthanum Carbonate (OLC) to treat hyperphosphatemia in CKD dialysis patients, aiming for a best-in-class therapy with reduced pill burden.